Skip to main content
. 2017 Feb 1;7:41018. doi: 10.1038/srep41018

Figure 2. M48U1 in 0.25% HEC and tenofovir in 0.25% HEC each inhibited several laboratory strains and patient-derived HIV-1 isolates.

Figure 2

Treatment with either 1 μM M48U1/0.25% (A) or 5 μM tenofovir/0.25% HEC (B) inhibited the replication of all tested laboratory and patient-derived strains. The HIV-1 strain tropism was determined with a sequencing analysis for the patient-derived strains. The combination of the two HIV-1 drugs inhibited HIV-1 replication independent of the HIV-1 strain tropism. HIV-1 replication was monitored by the HIV-1 p24 ELISA assay using cell culture supernatants obtained on day 7 post-infection. The data were expressed as the means ± standard deviations (±SD) of the level of HIV-1 gag p24 relative to untreated controls (set to 100%) for every HIV-1 strain. Three experiments in triplicate were performed. Analysis of antiretroviral activity of 1 μM M48U1 in 0.25% HEC (C) or 5 μM tenofovir in 0.25% HEC (D) performed in TZM-bl cells infected with pREJO.c/2864 and pTHRO.c/2626 T/F IMCs. The percentage of infection of each T/F was calculated comparing the relative luminescence units (RLUs) of the virus control wells, after subtraction of cell control RLUs and the data were expressed as the means ± standard deviations (±SD). Each sample was performed in triplicate and was repeated in three independent experiments.